HIV/AIDS and Opportunistic Infections — Clinical Documentation Guide (2026)

🔍 1. Definition

Human Immunodeficiency Virus (HIV) is a retrovirus that targets and destroys CD4+ T-lymphocytes (helper T-cells), progressively impairing cell-mediated immunity. Left untreated, HIV infection advances to Acquired Immunodeficiency Syndrome (AIDS), the most advanced stage, characterized by a CD4 count below 200 cells/µL or the development of an AIDS-defining illness. According to CDC, approximately 1.2 million Americans are living with HIV, and roughly 13% are unaware of their infection.

For coding purposes under FY2026 ICD-10-CM (CMS), the critical distinction is:

• B20 — HIV disease: Assigns when a patient has ever been diagnosed with AIDS or has an AIDS-defining condition (applies for life — once AIDS, always B20).
• Z21 — Asymptomatic HIV infection status: Assigns when HIV is confirmed but the patient has never had an AIDS-defining condition and is currently asymptomatic.
• R75 — Inconclusive laboratory evidence of HIV: Assigns when laboratory testing is inconclusive (e.g., indeterminate Western blot); never used as a confirmed HIV diagnosis.

🗂️ 2. Alternative Terminology

Clinicians, nurses, and patients may use varying language to refer to HIV/AIDS and related conditions. Coders and CDI specialists must recognize these terms to ensure complete and accurate documentation capture.

🩺 3. Signs & Symptoms

Clinical presentation varies significantly by stage of HIV infection. Early (acute) infection, chronic asymptomatic infection, and AIDS each present distinctly. Coders and CDI specialists should flag documented signs/symptoms that may signal transition from asymptomatic HIV (Z21) to AIDS (B20).

Acute HIV Infection (Seroconversion)

• Fever, night sweats, fatigue (flu-like illness 2–4 weeks after exposure)
• Pharyngitis, lymphadenopathy, rash (maculopapular)
• Myalgia, arthralgia, headache
• Oral ulcers, weight loss

Chronic Asymptomatic Phase (Z21)

• Generally no clinical signs; CD4 count typically >500 cells/µL
• Persistent generalized lymphadenopathy possible
• Mild thrombocytopenia or anemia may be present

AIDS-Defining Illness Triggers (→ B20)

• CD4 <200 cells/µL or CD4 percentage <14%
• Recurrent bacterial pneumonia (≥2 episodes in 12 months)
• Pneumocystis jirovecii pneumonia (PCP)
• Esophageal candidiasis
• CMV retinitis/disease
• Disseminated MAC/MAI
• Cerebral toxoplasmosis
• Cryptococcal meningitis
• HIV wasting syndrome (>10% involuntary weight loss)
• Kaposi sarcoma (any site)
• HIV-related lymphoma (C81–C86)
• Progressive multifocal leukoencephalopathy (PML)
• Invasive cervical cancer
• Pulmonary/extrapulmonary tuberculosis

🧭 4. Differential Diagnosis

Several conditions mimic HIV-related immunosuppression or present similarly to AIDS-defining illnesses. Coders must not assume HIV without explicit provider documentation.

📋 5. Clinical Indicators for Coders/CDI

The following clinical indicators should prompt a coder or CDI specialist to review the record for HIV/AIDS coding accuracy, OI documentation, and sequencing. Reference AHIMA and ACDIS resources for query standards.

🦴 6. Anatomy & Pathophysiology

Target Cells and Viral Life Cycle

HIV is an RNA retrovirus belonging to the genus Lentivirus. It primarily infects cells expressing the CD4 surface receptor, including CD4+ T-lymphocytes, macrophages, and dendritic cells. The virus binds CD4 via its gp120 envelope protein, requiring a coreceptor (CCR5 or CXCR4) for cell entry. After reverse transcription, viral DNA integrates into the host genome as a provirus — a reservoir that persists even with effective ART.

Immunological Cascade

Progressive CD4 cell depletion impairs cell-mediated immunity. Key thresholds per NIH AIDSinfo Clinical Guidelines:

• CD4 >500: Near-normal immune function; Z21 typical
• CD4 200–500: Moderate immunosuppression; risk of bacterial infections, herpes zoster
• CD4 <200: Severe immunosuppression; high risk for PCP, toxoplasmosis, CMV — AIDS threshold (B20)
• CD4 <50: Profound immunosuppression; disseminated MAC, CMV retinitis, cryptococcal meningitis

Opportunistic Infection Pathophysiology

• PCP (B59): Pneumocystis jirovecii reactivation causing diffuse alveolar damage; bilateral ground-glass infiltrates on CT; LDH typically elevated.
• CMV (B25.x): Reactivation of latent cytomegalovirus; retinitis (progressive blindness), colitis, esophagitis, encephalitis.
• Candidiasis (B37.x): Opportunistic fungal infection; esophageal form (B37.81) confirms AIDS-defining illness.
• Cryptococcosis (B45.x): Cryptococcus neoformans inhaled from soil; meningitis (B45.1) is the most common AIDS-defining CNS infection.
• Toxoplasmosis (B58.x): Reactivation of Toxoplasma gondii brain cysts causing ring-enhancing lesions; B58.2 = Toxoplasma encephalitis.
• MAC/MAI (A31.2): Disseminated Mycobacterium avium complex; fever, night sweats, weight loss, diarrhea, hepatosplenomegaly.
• TB (A15–A19): Reactivation TB highly prevalent in HIV; extrapulmonary TB more common with advanced immunosuppression.
• Kaposi sarcoma (C46.x): HHV-8 driven vascular tumor; skin lesions, visceral/pulmonary involvement possible; AIDS-defining cancer.

💊 7. Medication Impact / Treatment

Antiretroviral therapy (ART) is the cornerstone of HIV management and has transformed HIV from a terminal illness to a manageable chronic condition. Per NIH AIDSinfo 2026 ART Guidelines, treatment is recommended for all persons with HIV regardless of CD4 count.

Major ART Drug Classes (Coding Relevance)

• NRTIs (nucleoside/nucleotide reverse transcriptase inhibitors): tenofovir (TDF/TAF), emtricitabine, abacavir, lamivudine
• NNRTIs (non-nucleoside RTIs): efavirenz, rilpivirine, doravirine
• INSTIs (integrase strand transfer inhibitors): dolutegravir, bictegravir, raltegravir, cabotegravir
• PIs (protease inhibitors): darunavir/ritonavir, atazanavir/cobicistat
• Entry/attachment inhibitors: ibalizumab (J1742 HCPCS), fostemsavir, lenacapavir
• CCR5 antagonists: maraviroc
• Capsid inhibitors: lenacapavir (long-acting injectable)

OI Prophylaxis and Treatment

• PCP prophylaxis: TMP-SMX (trimethoprim-sulfamethoxazole); code Z29.81 for PCP prophylaxis
• MAC prophylaxis: Azithromycin (Q0144 HCPCS) when CD4 <50
• Toxoplasmosis prophylaxis: TMP-SMX double-strength
• Fluconazole: Candidal infections; J1400 (IV) or oral
• Ganciclovir/valganciclovir: CMV disease treatment
• Liposomal amphotericin B: Cryptococcal meningitis induction
• Ethambutol + rifampin + azithromycin: Disseminated MAC treatment
• Interferon alfa-2b (J1830): HIV-related Kaposi sarcoma

Medication Documentation Coding Notes

Long-term ART use is coded with Z79.899 (long-term current use of other medication) per FY2026 ICD-10-CM guidelines. Most oral ART agents are covered under Medicare Part D (prescription drug benefit), not Part B HCPCS — coders should note that J3490/J3590 apply to infused/injectable antiretrovirals administered in a clinical setting.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides